Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

2KEYNOTE-062 (P vs C ; CPS>10), 2020 KEYNOTE-062 (P vs C ; CPS>1), 20202CheckMate 649 (PDL1 CPS>5), 2021 CheckMate 649, 20212KEYNOTE-062 (PC vs C ; CPS>1), 2020 KEYNOTE-062 (PC vs C ; CPS>10), 2020nivolumab plus SoC vs. pembrolizumab alone 0.90 [0.73; 1.11]0.90 [0.73;1.11]nivolumab plus SoC vs. pembrolizumab alone 0.90 [0.73; 1.11]nivolumab plus SoC vs. pembrolizumab plus SoC 0.89 [0.73; 1.10]0.89 [0.73;1.10]nivolumab plus SoC vs. pembrolizumab plus SoC 0.89 [0.73; 1.10]nivolumab plus SoC vs. Standard of Care (SoC) nivolumab plus SoC better 0.76 [0.67; 0.86]0.76 [0.67;0.86]nivolumab plus SoC vs. Standard of Care (SoC) nivolumab plus SoC better 0.76 [0.67; 0.86]pembrolizumab alone vs. nivolumab plus SoC 1.12 [0.90; 1.38]1.12 [0.90;1.38]pembrolizumab alone vs. nivolumab plus SoC 1.12 [0.90; 1.38]pembrolizumab alone vs. pembrolizumab plus SoC 1.00 [0.79; 1.27]1.00 [0.79;1.27]pembrolizumab alone vs. pembrolizumab plus SoC 1.00 [0.79; 1.27]pembrolizumab alone vs. Standard of Care (SoC) 0.85 [0.71; 1.01]0.85 [0.71;1.01]pembrolizumab alone vs. Standard of Care (SoC) 0.85 [0.71; 1.01]pembrolizumab plus SoC vs. nivolumab plus SoC 1.12 [0.91; 1.37]1.12 [0.91;1.37]pembrolizumab plus SoC vs. nivolumab plus SoC 1.12 [0.91; 1.37]pembrolizumab plus SoC vs. pembrolizumab alone 1.00 [0.79; 1.27]1.00 [0.79;1.27]pembrolizumab plus SoC vs. pembrolizumab alone 1.00 [0.79; 1.27]pembrolizumab plus SoC vs. Standard of Care (SoC) 0.85 [0.72; 1.00]0.85 [0.72;1.00]pembrolizumab plus SoC vs. Standard of Care (SoC) 0.85 [0.72; 1.00]Standard of Care (SoC) vs. nivolumab plus SoC nivolumab plus SoC better 1.31 [1.16; 1.49]1.31 [1.16;1.49]Standard of Care (SoC) vs. nivolumab plus SoC nivolumab plus SoC better 1.31 [1.16; 1.49]Standard of Care (SoC) vs. pembrolizumab alone 1.18 [0.99; 1.40]1.18 [0.99;1.40]Standard of Care (SoC) vs. pembrolizumab alone 1.18 [0.99; 1.40]Standard of Care (SoC) vs. pembrolizumab plus SoC 1.18 [1.00; 1.39]1.18 [1.00;1.39]Standard of Care (SoC) vs. pembrolizumab plus SoC 1.18 [1.00; 1.39]Standard of Care (SoC)placebo plus SoCpembrolizumab alonenivolumab plus SoCpembrolizumab plus SoCdirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)placebo plus SoCpembrolizumab alonenivolumab plus SoCpembrolizumab plus SoC
Standard of Care (SoC)---NA1.18
0.99; 1.40		1.31
1.16; 1.49		1.18
1.00; 1.39
placebo plus SoCNA---NANANA
pembrolizumab alone0.85
0.71; 1.01		NA---1.12
0.90; 1.38		1.00
0.79; 1.27
nivolumab plus SoC0.76
0.67; 0.86		NA0.90
0.73; 1.11		---0.89
0.73; 1.10
pembrolizumab plus SoC0.85
0.72; 1.00		NA1.00
0.79; 1.27		1.12
0.91; 1.37		---

pathologies: 122,271,262,260,219,184 - treatments: 873 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons